Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
French drugmaker Sanofi is poised to commit between 1.3 billion euros and 1.5 billion euros ($1.4 billion – $1.6 billion) to enhancing its insulin production site in Frankfurt, Germany.
法國製藥公司賽諾菲安萬特將投入13-15億歐元（14-16億美元）提升其在德國法蘭克福的胰島素生產基地。
The site in Frankfurt's Hoechst district is known for producing the company's insulin brand, Lantus.
法蘭克福Hoechst區的該基地以生產公司的胰島素品牌Lantus而聞名。
Also Read: Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M.
夏威夷法院裁定反對百時美施貴寶和賽諾菲血栓藥物案，增加賠償金額至9.16億美元。
This move comes after initial plans to shift Lantus production to France were reconsidered.
此舉是在最初將Lantus的生產轉移到法國的計劃被重新考慮之後。
The decision to invest in the Frankfurt site represents a significant victory for Germany's healthcare sector.
投資法蘭克福基地的決定對德國的醫療保健行業來說是一個重大勝利。
Germany's ruling coalition has been actively working to attract healthcare investments. In February, Daiichi Sankyo announced plans to spend around 1 billion euros to advance its precision cancer drug work near Munich.
德國執政聯盟一直在積極爭取吸引醫療保健投資。今年2月，第一三共(Daiichi Sankyo)宣佈計劃在慕尼黑附近投資約10億歐元推進其精準癌症藥物工作。
Eli Lilly (NYSE:LLY) also committed 2.3 billion euros last November to produce obesity and diabetes medications in Germany.
去年11月，Eli Lilly (美國紐約證券交易所代碼LLY)也承諾在德國生產肥胖和糖尿病藥物的投資爲23億歐元。
Sanofi's investment is expected to bolster its production capabilities and reinforce its commitment to maintaining a strong manufacturing presence in Germany.
賽諾菲的投資預計將增強其生產能力，並加強其維持德國強大製造業存在的承諾
Reuters noted that the upgrade will likely enhance Lantus's supply chain stability and support Sanofi's long-term strategic goals.
路透社指出，升級將很可能增強Lantus的供應鏈穩定性，並支持賽諾菲的長期戰略目標。
In May, Sanofi announced an investment of more than €1 billion to create new bioproduction capacity at its French sites in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime), and Lyon Gerland (Rhône).
今年5月，賽諾菲宣佈投資超過10億歐元，在其法國位於瓦爾德馬恩(Vitry-sur-Seine)、特雷(Seine-Maritime)和里昂傑蘭(Rhône)的現有站點創造新的生物生產能力。
- Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC.
- 賽諾菲尋求出售價值200億美元的止痛貼膏業務：可能的競購者包括興業、PAI Partners、黑石和CVC。
Price Action: At the last check on Monday, SNY shares were up 1.96% at $49.47.
股價表現：在週一最後一次查詢時，賽諾菲股票上漲1.96%，報49.47美元。
Image by HJBC via Shutterstock
圖像來自Shutterstock用戶HJBC。
譯文內容由第三人軟體翻譯。